Companies
Funding, clinical milestones and business developments across longevity biotechnology, analysed with close attention to evidence, execution risk and company claims.
Longevica Wants to Turn a 16,000-Animal Longevity Screen Into New Drugs
Longevica says a $13 million screen tested 1,033 compounds in more than 16,000 mice. Its new advisory board may help build a…
Rejuvenation Technologies Gets New Backing for Telomere-Targeted mRNA Platform
Jetstream backed Rejuvenation Technologies’ targeted TERT mRNA platform. The programs remain preclinical, and funding is not clinical proof.
Canadian Biotech RejuvenRx Lands $1 Million to Advance Stem-Cell Aging Drugs
Stem Cell Network awarded Montreal biotech RejuvenRx $1 million to advance oral CoREST degraders. The drugs target blood stem-cell biology but remain…
BCG Sees a $350 Billion Gap in Women’s Longevity Care. What Does That Number Mean?
BCG estimates a $350 billion opportunity in women’s midlife longevity care. Its global survey points to unmet demand, while the dollar figure…
Magnitude Biosciences Raises £1.3 Million to Scale Drug Screening in Living Worms
The Durham spinout is expanding VivoScan, an automated whole-worm screening platform. The funding supports scale, but promising worm results still need mammalian…
Insilico Wants to Build a “Longevity Vaccine.” Here’s What Actually Exists So Far
Insilico’s “Longevity Vaccines” initiative proposes programming immune cells inside the body. Related mouse studies are encouraging, but the announcement offers no programme-specific…
Moonwalk Raises $70 Million as an Epigenetics Startup Moves Toward the Clinic
Moonwalk Biosciences raised a $70 million Series B to advance adipose-targeted RNAi medicines for obesity and cardiometabolic disease. Its epigenetics-based platform is…
Korsana Closes Cyclerion Merger With $380 Million War Chest for Alzheimer’s Drug Development
Korsana completed its merger with Cyclerion and closed a $380 million financing, giving the Alzheimer’s drug developer approximately $475 million in pro-forma…
SIRT6 Gene Therapy Lowered Biological Age in Old Dogs, Genflow Says. Where Is the Data?
Genflow says its randomized, blinded trial lowered a DNA methylation age score in older beagles. The result is intriguing, but detailed numerical…
AgelessRx Says a 90-Day Longevity Trial Improved Healthspan. What Did It Actually Show?
AgelessRx reported favorable changes from an 18-person final analysis. The randomized pilot generated signals, but it did not prove slower aging or…